Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-20, Stock:NVS, The news for the past five days is as follows:
2018-02-12: NEWS1: Bristol-Myers Squibb’s Oncology Portfolio in 4Q17.NEWS2: Regeneron Could Benefit From &apos;Lackluster&apos; Data Presented By These Rivals.NEWS3: Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017.NEWS4: Pfizer’s Inlyta: Analyzing Revenue Trends.NEWS5: Greek PM wants politicians investigated in alleged Novartis bribery case.NEWS6: Greek PM wants politicians investigated in alleged Novartis bribery case.NEWS7: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS8: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS9: How’s Pfizer’s Oncology Business Positioned after 2017?.NEWS10: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS11: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS12: Why Novartis’s Entresto Could Witness a Robust Demand Trend in 2018.NEWS13: What Could Drive Amgen’s Long-Term Growth?.NEWS14: How Much Profit Should Novartis Earn By Curing A Childhood Leukemia?.NEWS15: What’s Expected of Novartis’s Net Profit Margin in 2018?.NEWS16: The Swiss Stock Market Starts The Week With A Gain.NEWS17: The Swiss Stock Market Starts The Week With A Gain.NEWS18: European Markets Recover Some Lost Ground.NEWS19: European Markets Recover Some Lost Ground.NEWS20: GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018.NEWS21: European Shares Rebound From Six-month Lows.NEWS22: European Shares Rebound From Six-month Lows.NEWS23: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).NEWS24: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).
2018-02-13: NEWS1: Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug.NEWS2: Postponed Common Share Consolidation and Name Change.NEWS3: IIROC Trading Halt - NVS.NEWS4: Analyzing Pfizer’s Ibrance and Xalkori after 2Q17.NEWS5: Intercept Starts OCA Trial for NASH Patients With Cirrhosis.NEWS6: Intercept Starts OCA Trial for NASH Patients With Cirrhosis.NEWS7: Novartis gains U.S. approval for delayed MS drug.NEWS8: Teva shares drop 3% after rival generic product approved and launched.NEWS9: Pfizer’s Sutent Generated Higher Revenues in 4Q17.NEWS10: Novartis gains U.S. approval for delayed MS drug.NEWS11: The Swiss Stock Market Pulled Back On Inflation Concerns.NEWS12: The Swiss Stock Market Pulled Back On Inflation Concerns.NEWS13: Sandoz Announces FDA Approval Of Glatopa - Quick Facts.NEWS14: Sandoz Announces FDA Approval Of Glatopa - Quick Facts.
2018-02-14: NEWS1: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS2: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS3: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS4: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS5: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS6: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS7: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS8: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS9: IIROC Trade Resumption - NVS.NEWS10: IIROC Trade Resumption - NVS.NEWS11: The Swiss Stock Market Regained Some Lost Ground.NEWS12: The Swiss Stock Market Regained Some Lost Ground.NEWS13: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.NEWS14: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.
2018-02-15: NEWS1: Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales.NEWS2: Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales.NEWS3: VEA, NSRGY, NVS, TM: ETF Inflow Alert.NEWS4: VEA, NSRGY, NVS, TM: ETF Inflow Alert.NEWS5: Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva.NEWS6: Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva.NEWS7: 3 Tough Questions for Amgen.NEWS8: 3 Tough Questions for Amgen.NEWS9: Keytruda: Merck’s Largest Revenue Contributor in 4Q17.NEWS10: 3 Tough Questions for Amgen.NEWS11: 3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate.NEWS12: 3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate.NEWS13: The Swiss Stock Market Inched Higher As NestlÃ© Weighs.NEWS14: The Swiss Stock Market Inched Higher As NestlÃ© Weighs.NEWS15: Nestle FY Profit Down;to Explore Strategic Options For Its Gerber Life Insurance.NEWS16: Nestle FY Profit Down;to Explore Strategic Options For Its Gerber Life Insurance.NEWS17: Roche's Rituxan Gets Priority Review for Label Expansion.NEWS18: Roche's Rituxan Gets Priority Review for Label Expansion.
2018-02-16: NEWS1: GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year.NEWS2: How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients.NEWS3: Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug.NEWS4: Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles.NEWS5: Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017.NEWS6: Novartis readies to auction U.S. generic pills business - sources.NEWS7: Merck’s Human Vaccines Business in 4Q17.NEWS8: Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion.NEWS9: Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion.NEWS10: How Did Pfizer’s Legacy Established Products Segment Perform in 2017?.NEWS11: The Swiss Stock Market Extends Recovery And Finishes Week With A Gain.NEWS12: The Swiss Stock Market Extends Recovery And Finishes Week With A Gain.

Answer: Decrease